Drug Trial Radar · NCT06291376
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
Last checked: Nov 20, 2026Latest source record: Oct 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
584
Actual
Start
Mar 29, 2024
Primary completion
Jan 5, 2026
Study completion Jul 18, 2030
Sponsor
- Lead sponsor
- Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Mar 4, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study to evaluate efficacy of ravulizumab compared with placebo on proteinuria reduction and change in eGFR in adult participants with IgAN who are at risk of disease progression.
Conditions
- Immunoglobulin A Nephropathy
- IgAN
Interventions
RavulizumabDrug
Participants will receive ravulizumab via weight-based intravenous (IV) infusion.
PlaceboDrug
Participants will receive placebo via weight-based IV infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline in Proteinuria Based on 24-hour Urine Protein Creatinine Ratio (UPCR) at Week 34Time frame: Baseline, Week 34
- Change from Baseline in Glomerular Filtration Rate (eGFR) at Week 106Time frame: Baseline, Week 106
Locations
246 sites in 28 countries. Site status is shown where the registry gives one.
Research Site
Alabaster, Alabama
Research Site
Phoenix, Arizona
Research Site
Los Angeles, California
Research Site
Los Angeles, California
Research Site
Los Angeles, California
Research Site
Orange, California
Research Site
San Bernardino, California
Research Site
San Diego, California
Research Site
San Francisco, California
Research Site
Stanford, California
Research Site
Torrance, California
Research Site
Valencia, California
Research Site
Bay Pines, Florida
Research Site
Miami, Florida
Research Site
Orlando, Florida
Research Site
Acworth, Georgia
Research Site
Atlanta, Georgia
Research Site
Lawrenceville, Georgia
Research Site
New Orleans, Louisiana
Research Site
Boston, Massachusetts
Research Site
Boston, Massachusetts
Research Site
Boston, Massachusetts
Research Site
Worcester, Massachusetts
Research Site
Minneapolis, Minnesota
Research Site
Minneapolis, Minnesota
Research Site
Kansas City, Missouri
Research Site
North Las Vegas, Nevada
Research Site
Albany, New York
Research Site
New York, New York
Research Site
The Bronx, New York
Research Site
Columbus, Ohio
Research Site
Knoxville, Tennessee
Research Site
Arlington, Texas
Research Site
Houston, Texas
Research Site
Houston, Texas
Research Site
San Antonio, Texas
Research Site
Shenandoah, Texas
Research Site
Charlottesville, Virginia
Research Site
Milwaukee, Wisconsin
Research Site
Ciudad de Buenos Aires, Argentina
Showing 40 of 246 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.